Engineered Extracellular Vesicle-Delivered CRISPR/Cas9 for Radiotherapy Sensitization of Glioblastoma

[Image: see text] Radiotherapy is a mainstay of glioblastoma (GBM) treatment; however, the development of therapeutic resistance has hampered the efficacy of radiotherapy, suggesting that additional treatment strategies are needed. Here, an in vivo loss-of-function genome-wide CRISPR screen was carr...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiao, Cao, Zhengcong, Wang, Weizhong, Zou, Cheng, Wang, Yingwen, Pan, Luxiang, Jia, Bo, Zhang, Kuo, Zhang, Wangqian, Li, Weina, Hao, Qiang, Zhang, Yingqi, Zhang, Wei, Xue, Xiaochang, Lin, Wei, Li, Meng, Gu, Jintao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510715/
https://www.ncbi.nlm.nih.gov/pubmed/37646615
http://dx.doi.org/10.1021/acsnano.2c12857

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510715/
https://www.ncbi.nlm.nih.gov/pubmed/37646615
http://dx.doi.org/10.1021/acsnano.2c12857

Ejemplares similares